Zitera

Quick links to important sections

Zitera

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zitera

Quick Facts: Zitera (Levetiracetam)

Property Description
Active ingredient Levetiracetam
Form Tablet (IR/ER), Oral Solution, IV Infusion
Pharmacological class Antiepileptic Drug (AED) / Anticonvulsant
Common use Modulation of brain electrical activity
Origin Synthetic Pyrrolidine derivative

What Type of Medicine is Zitera?

Zitera is a prescription-only medication classified as an Antiepileptic Drug (AED), a group of agents used to stabilize excessive electrical activity in the brain. Its therapeutic core is the single active component, Levetiracetam, a synthetic molecule belonging to the pyrrolidine class of compounds. Levetiracetam possesses a unique action profile that distinguishes it from many older-generation anticonvulsants. Its distinct chemical structure allows it to manage conditions characterized by recurrent, abnormal electrical bursts. The general purpose of this medicine is to modulate the brain's environment, which helps raise the threshold for abnormal electrical discharges.


Composition and Available Preparations

The composition of Zitera utilizes Levetiracetam, a highly water-soluble chemical, in various preparations for both oral and intravenous administration. As a single-agent product, Zitera is offered in both immediate-release and extended-release tablets, an oral liquid solution, and a concentrate for intravenous (IV) infusion. The availability of the oral solution is a key differentiating factor, making the medicine suitable for patients who may have difficulty swallowing solid dosage forms. The IV preparation ensures that the anticonvulsant effect can be maintained temporarily when oral intake is not feasible, which is often necessary in hospital settings.


How Does Zitera Relate to Brain Activity?

Zitera works by selectively binding to the protein Synaptic Vesicle Glycoprotein 2A (SV2A) found on nerve endings, an action recognized for its effectiveness in stabilizing nerve signaling. This mechanism is central to Levetiracetam’s ability to interfere with the rapid, uncontrolled electrical signaling in the brain. This targeted modulation supports the stability of neural networks. The therapeutic benefit is tied to controlling nerve cell hyperexcitability, thus aiming to reduce the frequency of seizure events.

Regulatory References

  1. NIH LiverTox: Levetiracetam

What side effects are possible with Zitera?

The safety characteristics of Zitera (Levetiracetam) are defined by adverse reactions classified by frequency and system involvement, as documented in official regulatory sources.

Frequency and System Classification

Adverse reactions are grouped into categories based on reporting frequency, with the most common effects involving the Nervous System and Psychiatric Disorders. The most frequently reported effects, categorized as Very Common (ge 10% incidence), include somnolence (sleepiness) and headache in adults. Effects categorized as Common (ge 1% to <10% incidence) include asthenia (loss of strength), fatigue, dizziness, and behavioral changes such as aggression and irritability.


Serious Safety Considerations and Constraints

Regulatory warnings note the potential for serious adverse reactions, including life-threatening immune responses such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Stevens-Johnson Syndrome (SJS). As with all antiepileptic medicines, there is an established risk of suicidal ideation and behavior.

Safety notes specify that behavioral side effects may be more frequently observed at the beginning of treatment. Furthermore, the clearance of Levetiracetam is primarily via the kidneys, meaning dose adjustments are required for patients with renal impairment. The official label requires that the medicine must not be abruptly discontinued, as this may increase the frequency of seizures.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the officially documented manifestations and mandated actions for a suspected overdose of Zitera (Levetiracetam), based strictly on government regulatory documents.

Domain Official Regulatory Statement
Documented Overdose Presentations Symptoms observed include somnolence, agitation, aggression, and a depressed level of consciousness
Physiological Systems Affected Central Nervous System (CNS) and the Respiratory System (manifesting as respiratory depression)
Dose-related or Exposure-related Factors Accidental overdose with the oral solution has been reported, predominantly in children aged 6 months to 11 years, often related to using an inappropriate dosing device
When Immediate Medical Help is Required Immediate medical attention must be sought for a suspected overdose, particularly if severe signs such as coma or respiratory depression are present
Classification Official Regulatory Statement
Severity Classification Recognized outcomes include coma and respiratory depression, which are classified as severe, life-threatening events requiring urgent medical intervention
Antidote Status No specific antidote is known for Levetiracetam overdose

Official Overdose Management Statements

Official prescribing information mandates that treatment for overdose is symptomatic and supportive. Elimination of unabsorbed drug should be considered through procedures like emesis (induced vomiting) or gastric lavage (stomach washout), with appropriate airway protection. Furthermore, Haemodialysis is documented as a procedure that can remove a significant amount of Levetiracetam from the blood, and should be considered based on the patient's clinical status.


Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile of Zitera by identifying the common central nervous system manifestations and the risk of severe complications, such as respiratory depression and coma. This documented risk necessitates the explicit regulatory mandate that immediate medical attention be sought in all cases of suspected overdose. The treatment pathway is constrained by the official statement that no specific antidote is known, thus establishing management based on supportive care and the potential for clearance via haemodialysis.

Therapeutic Uses of Zitera

Zitera is applied across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms associated with epilepsy.

Uses and Benefits of Zitera


Zitera is commonly used across conditions presenting with acute episodes of seizure activity. The medication is relevant in clinical settings where supportive symptom management is appropriate, helping to manage symptoms of increased neurological activity. It is applied to address symptom clusters that may become intense or disruptive in three primary areas: partial-onset seizures, primary generalized tonic-clonic seizures, and myoclonic seizures associated with Juvenile Myoclonic Epilepsy.

“The therapy is often used when groups of symptoms appear suddenly or fluctuate, providing support that helps ease the overall symptom burden.”

This supportive approach contributes to improved comfort during symptomatic periods and may help patients cope more steadily with symptom fluctuations, assisting with maintaining functional stability.

Quick Fact: Support for Neurological Discomfort Zitera is applied in scenarios where additional management of discomfort is required in conditions involving recurrent or episodic manifestations of heightened neurological activity.

Regulatory References

  1. European Medicines Agency (EMA) overview of Keppra's uses

Eligibility and Restrictions for Use

Zitera (Levetiracetam) is a prescription medicine with eligibility rules strictly defined by regulatory authorities based on age, physiological status, and organ function.

Contraindicated Populations

  • Hypersensitivity: Use is absolutely contraindicated in patients with a known allergy or hypersensitivity to Levetiracetam or other pyrrolidone derivatives.

Age-Related Eligibility

Age Group Eligibility Status (Regulatory Basis)
Adults ( ge 16 years) Eligible for all approved uses, including monotherapy.
Pediatric Patients Approved for adjunctive therapy for partial-onset seizures down to 1 month of age (EMA) and 4 years of age (FDA).
Monotherapy Restriction Use as a single agent is not established for children and adolescents below 16 years of age.

Conditional Use and Restrictions

  • Renal Impairment: Eligibility is conditional. Since the medicine is primarily cleared by the kidneys, patients with any degree of impaired renal function (kidney problems), including the elderly, must have their use managed under mandatory adjustment rules.
  • Pregnancy and Lactation: Use during pregnancy is permitted but requires close monitoring by a clinician, as regulatory data show plasma levels may decrease. Use while breastfeeding is not recommended by the manufacturer due to excretion into human milk.
  • Behavioral History: Patients with a history of behavioral abnormalities or depression are eligible but require close monitoring and caution during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zitera (Levetiracetam) has an official interaction profile characterized by minimal involvement in the body's major drug metabolism systems but still requires caution with specific co-administered substances, as documented by regulatory agencies.


Pharmacokinetic and Pharmacodynamic Interactions

Category Official Regulatory Documentation
Interacting Medicines Enzyme-inducing Antiepileptic Drugs (e.g., Carbamazepine, Phenytoin) and CNS Depressants (e.g., Opioids, Benzodiazepines)
Mechanistic Basis PK Clearance Alteration (Increased clearance with enzyme inducers); PD Reinforcement (Additive CNS effects)
Restriction Co-administration with enzyme-inducing antiepileptic drugs is associated with an increase in Levetiracetam's apparent clearance by approximately 22%.
Metabolic Profile Levetiracetam is unlikely to produce or be subject to significant CYP-mediated pharmacokinetic interactions, as it is not extensively metabolized by major liver cytochrome P450 enzymes.

Administration and Population Constraints

Category Official Regulatory Documentation
Timing-based Rule The osmotic laxative Macrogol must not be taken for one hour before and one hour after oral Zitera administration due to documented reports of decreased efficacy.
Food/Alcohol Status May be taken with or without food. No specific data on interaction with alcohol is available in the product information, but additive CNS effects are a general consideration.
Population Note Patients with renal impairment are subject to altered drug clearance, which is directly correlated with creatinine clearance, resulting in a reduced elimination rate of the drug.

The official interaction statements primarily confirm the limited risk associated with hepatic metabolism but mandate specific constraints related to clearance modification, timing separation, and additive CNS effects.

Mechanism of Action

Modulating the Synaptic Vesicle Glycoprotein 2A ( SV2A)

Zitera's core mechanism involves the selective binding and modulation of the Synaptic Vesicle Glycoprotein 2A ( SV2A) protein, an essential component of the nerve cell machinery responsible for releasing chemical signals. This targeted interaction alters the function of SV2A to initiate the molecular cascade resulting in altered neuronal excitability.


Constraining Excitatory Neurotransmitter Release

By altering the dynamics of the SV2A protein, Zitera constrains the synchronous, excessive release of excitatory neurotransmitters, such as glutamate, from the nerve ending. This targeted interference with chemical signaling strengthens the neural network's intrinsic threshold, limiting the propagation of synchronous, high-frequency neuronal discharges across the CNS circuits.


Modulating Neural Network Firing Patterns

The overall consequence of this presynaptic modulation is the alteration of synchronous neuronal firing patterns. This mechanism contributes to modulating the excitability of neuronal tissue by raising the functional resistance of brain tissue to widespread electrical hyperexcitability.

Dosage and Administration Information

How to Use Zitera: Official Administration Guidelines

The usage of Zitera (Levetiracetam) is defined by a standardized set of instructions covering administration route, dose, and frequency, as outlined in official guidelines. These guidelines focus strictly on the labeled procedures for use, not clinical rationale or outcomes.


Administration Scope

Instruction Category Official Guideline
Route of Administration Primarily Oral (tablets, solution); temporarily Intravenous (IV) Infusion when oral intake is interrupted.
Dosing Schedule (Adults) Initial dose is typically 500 mg twice daily. The dose is gradually increased every two weeks based on response, up to a maximum daily total of 3000 mg.
Formulation Schedule Immediate-Release (IR) and IV formulations are administered twice daily (every 12 hours). Extended-Release (ER) tablets are taken once daily.
Relation to Meals Oral formulations may be taken with or without food.

Special Procedural Conditions

Instruction Category Official Guideline
Special Handling Extended-Release (ER) tablets must be swallowed whole and must not be chewed, crushed, or broken.
IV Administration The IV formulation must be administered as a 15-minute infusion. The total daily IV dose must be equivalent to the oral daily dose.
Population Adjustment Mandatory dose reduction is required for patients with confirmed renal (kidney) impairment, with specific schedules for those on dialysis.
Discontinuation Withdrawal from Zitera must be gradual through dose reduction over time to minimize the potential for abrupt changes in usage patterns.

The official protocol establishes that treatment begins with a low, conservative dose that is incrementally increased based on a defined schedule, known as titration. The instructions dictate precise administration methods for each form (oral vs. IV, IR vs. ER) and mandate dose modification linked to the patient's renal function status.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zitera

This overview summarizes the official clinical research and trials conducted on Zitera (Levetiracetam), focusing on the types of studies performed, the patient groups evaluated, and what the collected evidence suggests according to regulatory and scientific literature.


Evidence for use in Partial-Onset Seizures

Zitera was studied for use in patients experiencing partial-onset seizures. The core evidence comes from short-term, randomized controlled trials (RCTs). Researchers explored how symptoms change over time when Zitera was used as an add-on treatment, and studies also examined its use as a single substance (monotherapy), including comparisons with other treatments. The main outcomes measured included quantifying the change in seizure frequency and assessing the number of patients who achieved a specific, pre-defined reduction in seizure count.

Studies reported how symptoms evolved in the observed populations, with frequency measurements assessed against the placebo group when Zitera was used as an add-on. Active-controlled trials in newly diagnosed adults documented seizure cessation rates in the context of comparison with certain older standard treatments. Long-term outcomes regarding the sustained maintenance of reduced seizure frequency are not fully established beyond the intermediate follow-up periods of the initial trials.


Evidence for use in Primary Generalized Tonic-Clonic Seizures (PGTCS) and Myoclonic Seizures

For Primary Generalized Tonic-Clonic Seizures (PGTCS) and Myoclonic Seizures (associated with Juvenile Myoclonic Epilepsy, JME), the evidence structure is primarily built upon short-term, double-blind, placebo-controlled RCTs. The outcomes measured included the median percent reduction in weekly seizure frequency and the rate of achieving a seizure freedom rate.

Controlled evaluations documented measurements of frequency change in the group receiving Zitera in comparison with the placebo group. The existing data primarily pertains to the short-term effects of Zitera when used as an add-on treatment. A primary research limitation frame is that comparative evidence is lacking in several areas against alternative established treatments.


Evidence Gaps and Special Populations

Research has explored Zitera across a wide pediatric age spectrum, including infants and children, for partial-onset seizures. However, data for certain groups remain insufficient. For example, for PGTCS, the evidence structure in patients under the age of 12 is more limited. The research cannot predict whether an individual will respond similarly, especially when considering the variability noted in post-marketing reports.

Frequently Asked Questions (FAQ)

Common questions about Zitera (FAQ)


Q: How quickly do people typically start to notice the effects of Zitera?

Studies and official information indicate that clinical trials measure seizure reduction over a period of time. However, the regulatory label does not provide a specific timeframe for when a person is expected to notice the initial effects. The information focuses on efficacy measured over the course of the clinical trials.


Q: Can older adults safely use Zitera?

According to the official product information, use in elderly patients (age 65 and older) is permitted. However, because the medicine is cleared by the kidneys, official instructions note that dose adjustment may be necessary if kidney function is reduced.


Q: What is the difference between Zitera and a standard [Type of treatment/drug class]?

Regulatory documents state that Zitera is classified as an Antiepileptic Drug (AED). Its mechanism of action is considered unique because it works by selectively binding to a protein called Synaptic Vesicle Glycoprotein 2A (SV2A). This mechanism of action is noted as unique when compared to many older AEDs.


Q: Are there any known long-term side effects of taking Zitera for many years?

Studies and official information indicate that clinical trial evidence for sustained, long-term outcomes beyond intermediate follow-up periods is not fully established. Ongoing post-marketing surveillance continues to monitor the sustained safety profile.


Q: How does Zitera affect driving or operating machinery?

The official product information contains a warning that the medicine may cause fatigue and somnolence (sleepiness). For this reason, the label advises that a person should not drive or operate complex machinery until they are aware of how the medicine affects them.


Q: Does Zitera need to be taken at a specific time of day?

Regulatory documents state that the Immediate-Release (IR) formulation is prescribed to be taken twice daily, which is typically every 12 hours. The Extended-Release (ER) tablet is prescribed to be taken once daily. This medicine can generally be taken with or without food.


Q: What are people's experiences when stopping Zitera after long-term use?

Official regulatory guidelines mandate that this medicine must be withdrawn gradually through dose reduction over time. This procedure is necessary to minimize the potential for increased seizure frequency or the occurrence of withdrawal seizures.


Q: What does 'contraindication' mean in the context of Zitera?

A contraindication refers to a condition where the medicine is not to be used. According to the official product information, this medicine is contraindicated if a person has a known allergy or hypersensitivity to the active ingredient, Levetiracetam, or other related substances.


Q: Is Zitera considered a first-line treatment for its main uses?

Regulatory documentation establishes that the medicine is approved for use in certain conditions as monotherapy (use as a single substance) and for other uses as adjunctive therapy (an add-on treatment). These approved uses define its regulatory status.


Q: What happens if I miss a scheduled time for taking Zitera?

Official patient information advises that a missed dose should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. If that is the case, the instruction is to skip the missed dose and resume the normal schedule. Official instructions advise against ever taking a double dose.


Q: Does Zitera cause weight gain or weight loss?

Official product information lists changes in weight as a reported adverse reaction. Clinical trials reported both a decrease in weight and an increase in weight among some patients during treatment.


Q: Is there a generic version of Zitera available?

Official regulatory data confirms that generic versions of the medicine, containing the active ingredient Levetiracetam, have been approved by the FDA. The availability of generics is confirmed via its Abbreviated New Drug Application (ANDA) status.


Q: What should be done if someone accidentally takes too much Zitera?

According to official documents on overdosage, symptoms may include somnolence, agitation, and aggression. The official documents state that management involves symptomatic treatment, and note that the active ingredient can be removed from the body using a procedure called hemodialysis.


Q: Does Zitera affect blood pressure or heart rate?

Official product information indicates that some patients, particularly infants and children, have experienced an increase in diastolic blood pressure in clinical studies. Effects on heart rate are not generally highlighted in the label summary.


Q: What is the risk of dependence or addiction with Zitera?

Regulatory documentation states that the active ingredient, Levetiracetam, is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). The classification as a non-controlled substance is relevant to its risk profile concerning dependence.


Q: Does Zitera require special monitoring or blood tests during treatment?

According to official guidance, routine monitoring of drug levels in the blood is generally not necessary. However, the label notes the potential for hematologic abnormalities and official guidance mentions that assessment of kidney function may be warranted for certain patients.


Q: Can Zitera be taken with over-the-counter pain relievers like ibuprofen?

Official regulatory documents do not list a specific interaction with single-ingredient pain relievers such as ibuprofen. Regulatory information notes a general caution regarding co-administration with any medication that may cause Central Nervous System (CNS) depression or affect kidney function.


Q: Do studies suggest that Zitera has different effects on men versus women?

Official product information indicates that the medicine's clinical pharmacology profile does not suggest that dose adjustments are necessary based solely on the sex of the patient.


Q: Does Zitera interact with common herbal supplements like St. John's wort?

The official interaction statements caution against combining the medicine with any substance or supplement that may cause additive central nervous system (CNS) effects. St. John's wort is known to have this potential interaction, which is noted due to the risk of additive CNS effects, such as increased sleepiness or dizziness.


Q: Can I take Zitera if I have a history of liver disease?

Official product information states that no dose adjustment is typically needed for patients with mild to moderate liver impairment. However, dose reduction may be recommended in cases of severe liver impairment if the patient also has reduced kidney function.


Q: Are there any specific lifestyle changes recommended while using Zitera?

Official warnings and instructions note temporary precautions, such as the need to avoid driving or operating machinery until stable on the medicine. Additionally, a general caution is advised regarding substances like alcohol that can cause additive Central Nervous System (CNS) effects.


Q: What if I experience unusual dreams while taking Zitera?

The official product information lists various sleep disturbances and psychiatric conditions in the adverse events section. Changes to sleep patterns or unusual dreams are generally noted under these related categories.


Q: Is Zitera a controlled substance?

Official regulatory documentation states that the active ingredient, Levetiracetam, is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA).


Q: What should be in my medicine kit when traveling with Zitera?

The official storage requirements recommend keeping the medicine at controlled room temperature and in its original, tightly closed container. Following these requirements helps maintain stability and protects the medicine from moisture and heat.


Q: Does Zitera interfere with birth control pills?

Clinical studies reviewed by regulatory agencies indicate that this medicine is not expected to affect the pharmacokinetics (how the body handles the drug) or the contraceptive efficacy of common oral birth control pills containing hormones like ethinyl estradiol.


Q: How long does it take for Zitera to completely leave the body?

According to official pharmacokinetic data, the plasma elimination half-life in adults with normal kidney function is typically 6 to 8 hours. This half-life is the time required for the amount of medicine in the body to decrease by half.


Q: Is it normal to feel a mild stomach upset when starting Zitera?

The official product label lists Gastrointestinal (GI) side effects in its adverse events section. These reported effects include abdominal pain, nausea, and vomiting.


Q: Do any studies look at the use of Zitera in diverse patient populations?

Regulatory documents contain specific information on use in different populations, including a wide pediatric age spectrum (infants and children), the elderly, and patients with renal impairment (kidney problems).


Q: Why is Zitera sometimes not recommended for people with heart conditions?

Official product information does not list a general heart condition contraindication. However, the label does note that some patients, particularly infants and children, have experienced an increase in blood pressure, which is a cardiovascular parameter noted in the regulatory information.


Q: Are there any restrictions on donating blood while taking Zitera?

Guidelines from government-affiliated blood services typically include rules for donors who are taking anti-seizure medication. These guidelines typically relate eligibility to factors such as being seizure-free for a specified time period.

How should Zitera be stored and disposed of?

The storage and disposal of Zitera (Levetiracetam) must adhere strictly to official regulatory guidelines to ensure product stability and environmental safety.

Storage Requirements

  • Temperature: Store tablets, oral solution, and concentrate at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The oral solution must not be frozen or refrigerated.
  • Protection: Keep the medication in the original, tightly closed container and store it away from excess heat and moisture.
  • Stability: The oral solution must be used within four months (120 days) after the bottle is first opened. Diluted IV solution is generally stable for 24 hours at room temperature.
  • Child Safety: Keep this medication out of the sight and reach of children.

Disposal Instructions

Unused or expired product should not be disposed of in household trash or wastewater (e.g., flushed down the toilet). Disposal must be done via established pharmaceutical take-back programs or by following the instructions of a healthcare professional to minimize environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zitera found in:

A-Z Index: